John Y Fang1, Adriana Pérez2, Chadwick W Christine3, Maureen Leehey4, Michael J Aminoff5, James T Boyd6, John C Morgan7, Rohit Dhall8, Anthony P Nicholas9, Ivan Bodis-Wollner10, Richard M Zweig11, John L Goudreau12. 1. Department of Neurology, Vanderbilt University, 1161 21st Ave South, A-0118, Nashville, TN 37232, USA. Electronic address: john.y.fang@vanderbilt.edu. 2. UTHealth, The University of Texas School of Public Health, Austin Regional Campus, University of Texas Administration Building (UTA), 1616 Guadalupe Street, Suite 6.300, Austin, TX 78701, USA. 3. Department of Neurology, University of California at San Francisco, 400 Parnassus Ave, Box 0348, San Francisco, CA 94143, USA. 4. Department of Neurology, University of Colorado School of Medicine, Academic Office 1, Mail Stop B-185, 12631 East 17th Avenue, Aurora, CO 80045, USA. 5. Department of Neurology, School of Medicine, University of California at San Francisco, 505 Parnassus Ave, Box 0114, San Francisco, CA 94143-0114, USA. 6. Department of Neurological Sciences, University of Vermont College of Medicine, 1 South Prospect Street, Burlington, VT 05401, USA. 7. Movement and Cognitive Disorders Center, Department of Neurology, Medical College of Georgia, Georgia Regents University, 1429 Harper Street, HF-1154, Augusta, GA 30912, USA. 8. Barrow Neurological Institute, 240 W Thomas Road, Suite 301, Phoenix, AZ 85013, USA. 9. Department of Neurology, University of Alabama at Birmingham and The Birmingham VA Medical Center, 1720 2nd Avenue South, Birmingham, AL 35294, USA. 10. Department of Neurology, State University of New York, Downstate Medical Center, 450 Clarkson Ave, Brooklyn, NY 11203, USA; Department of Ophthalmology, State University of New York, Downstate Medical Center, 450 Clarkson Ave, Brooklyn, NY 11203, USA. 11. Department of Neurology, LSU Health Sciences Center in Shreveport, 1501 King's Highway, Shreveport, LA 71130, USA. 12. Department of Neurology, Michigan State University, 804 Service Rd, Room A217, USA.
Abstract
BACKGROUND: The effects of dopaminergic therapy in parkinson's disease (PD) can vary depending on the class of medication selected. OBJECTIVE: The aim of this post hoc study was to determine if the class of dopaminergic therapy correlated with disease severity in persons with early, treated PD. METHODS: A non-parametric global statistical test (GST) was used to assess the status of participants treated with dopamine agonist (DA) monotherapy, levodopa (LD) monotherapy or combined LD and DA therapy on multiple PD outcomes encompassing motor, cognitive, psychiatric and autonomic function, as well as disability and quality of life. RESULTS: The outcomes measured at the beginning of the study showed lower disease burden for participants on initial DA monotherapy compared to those taking combined LD and DA therapy after controlling for age, education, taking cog-meds and amantadine. CONCLUSION: This observation suggests that clinicians treating early PD patients favor combined LD and DA therapy in patients with more disabling features over DA monotherapy. As such, studies of PD progression in treated PD patients may be affected by the class of symptomatic dopaminergic therapy. Published by Elsevier Ltd.
BACKGROUND: The effects of dopaminergic therapy in parkinson's disease (PD) can vary depending on the class of medication selected. OBJECTIVE: The aim of this post hoc study was to determine if the class of dopaminergic therapy correlated with disease severity in persons with early, treated PD. METHODS: A non-parametric global statistical test (GST) was used to assess the status of participants treated with dopamine agonist (DA) monotherapy, levodopa (LD) monotherapy or combined LD and DA therapy on multiple PD outcomes encompassing motor, cognitive, psychiatric and autonomic function, as well as disability and quality of life. RESULTS: The outcomes measured at the beginning of the study showed lower disease burden for participants on initial DA monotherapy compared to those taking combined LD and DA therapy after controlling for age, education, taking cog-meds and amantadine. CONCLUSION: This observation suggests that clinicians treating early PDpatients favor combined LD and DA therapy in patients with more disabling features over DA monotherapy. As such, studies of PD progression in treated PDpatients may be affected by the class of symptomatic dopaminergic therapy. Published by Elsevier Ltd.
Authors: Olivier Rascol; David J Brooks; Amos D Korczyn; Peter P De Deyn; Carl E Clarke; Anthony E Lang; Mona Abdalla Journal: Mov Disord Date: 2006-11 Impact factor: 10.338
Authors: Robert G Holloway; Ira Shoulson; Stanley Fahn; Karl Kieburtz; Anthony Lang; Kenneth Marek; Michael McDermott; John Seibyl; William Weiner; Bruno Musch; Cornelia Kamp; Mickie Welsh; Aileen Shinaman; Rajesh Pahwa; Lynn Barclay; Jean Hubble; Peter LeWitt; Janis Miyasaki; Oksana Suchowersky; Mark Stacy; David S Russell; Blair Ford; John Hammerstad; David Riley; David Standaert; Frederick Wooten; Stewart Factor; Joseph Jankovic; Farah Atassi; Roger Kurlan; Michel Panisset; Ali Rajput; Robert Rodnitzky; Cliff Shults; Giselle Petsinger; Cheryl Waters; Ronald Pfeiffer; Kevin Biglan; Leona Borchert; Amy Montgomery; Laura Sutherland; Carolyn Weeks; Maryan DeAngelis; Elspeth Sime; Susan Wood; Carol Pantella; Mary Harrigan; Barbara Fussell; Sandra Dillon; Barbara Alexander-Brown; Pamela Rainey; Marsha Tennis; Elke Rost-Ruffner; Diane Brown; Sharon Evans; Debra Berry; Jean Hall; Theresa Shirley; Judith Dobson; Deborah Fontaine; Brenda Pfeiffer; Alicia Brocht; Susan Bennett; Susan Daigneault; Karen Hodgeman; Carolynn O'Connell; Tori Ross; Karen Richard; Arthur Watts Journal: Arch Neurol Date: 2004-07
Authors: Richard Gray; Natalie Ives; Caroline Rick; Smitaa Patel; Alastair Gray; Crispin Jenkinson; Emma McIntosh; Keith Wheatley; Adrian Williams; Carl E Clarke Journal: Lancet Date: 2014-06-11 Impact factor: 79.321